(Q34630777)

3 August 2017

1 reference

title

The search for optimal treatment in relapsed and refractory acute myeloid leukemia (English)

1 reference

3 August 2017

1

Tadeusz Robak

1 reference

3 August 2017

2

Agata Wrzesień-Kuś

1 reference

3 August 2017

language of work or name

1 reference

1 February 2002

1 reference

3 August 2017

1 reference

3 August 2017

volume

43

1 reference

3 August 2017

issue

2

1 reference

3 August 2017

page(s)

281-291

1 reference

The treatment of acute leukaemia

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10428190290006053

Treatment of acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290006053

Treatment and prognostic factors in acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290006053

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290006053

Cytogenetic subgroups in acute myeloid leukemia differ in proliferative activity and response to GM-CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290006053

Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290006053

MDR1 expression in poor-risk acute myeloid leukemia with partial or complete monosomy 7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290006053

Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290006053

Timed sequential chemotherapy for advanced acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290006053

Management of relapsed acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290006053

Duration of second complete remission compared with first complete remission in patients with acute myeloid leukemia. Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290006053

Techniques for detection of minimal residual disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290006053

Reversal of multidrug resistance in hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290006053

Mutations in ras proto-oncogenes are associated with lower mdr1 gene expression in adult acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290006053

The drug resistance-related protein LRP is the human major vault protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290006053

Multidrug resistance in acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290006053

Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290006053

Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290006053

Cyclosporin increases cellular idarubicin and idarubicinol concentrations in relapsed or refractory AML mainly due to reduced systemic clearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290006053

Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290006053

A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a southwest oncology group study 9617.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290006053

MDR modulation in acute myelogenous leukemia: is it dead?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290006053

Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290006053

A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290006053

Sensitization by 5-aza-2'-deoxycytidine of leukaemia cells with MLL abnormalities to induction of differentiation by all-trans retinoic acid and 1alpha,25-dihydroxyvitamin D3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290006053

Telomerase activity and telomere length in pediatric patients with malignancies undergoing chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290006053

Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290006053

Liposomal drug formulations. Rationale for development and what we can expect for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290006053

Treatment of newly diagnosed and relapsed acute promyelocytic leukemia with intravenous liposomal all-trans retinoic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290006053

Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290006053

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290006053

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290006053

RAS and leukemia: from basic mechanisms to gene-directed therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290006053

Targeted AML therapy: new biologic paradigms and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290006053

Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290006053

Malignancy: Gene Therapy Vaccines in Acute Myeloid Leukemia : A Need for Clinical Evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290006053

Potential for therapy with AML-derived dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290006053

A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290006053

The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290006053

Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Par

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290006053

Autologous bone marrow transplantation for acute myeloid leukemia in remission or first relapse using monoclonal antibody-purged marrow: results of phase II studies with long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290006053

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290006053

Marrow vs peripheral blood: impact on transplant outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290006053

Nonmyeloablative preparative regimens: how relevant for acute myelogenous leukemia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290006053

Treatment of leukemic relapse after allogeneic stem cell transplantation with cytotoreductive chemotherapy and/or immunotherapy or second transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290006053

Roquinimex (Linomide) vs placebo in AML after autologous bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290006053

10.1080/10428190290006053

21 January 2018

Identifiers

DOI

1 reference

release_5vmg6breebalbj6zamfcq77ufe

3 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/5vmg6breebalbj6zamfcq77ufe

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference